chromosome 6 open reading frame 120Genealiases: []
Q-omics provides the consensus-scored C6orf120 profile across patient tissues and cancer cell-line models. C6orf120 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, C6orf120 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, C6orf120 RNA expression shows 19,880 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where C6orf120 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C6orf120 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C6orf120 survival associations across molecular data types. C6orf120 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C6orf120 RNA expression–survival associations across cancer types. High C6orf120 expression shows unfavorable associations in BLCA, CESC, OV and STAD, but favorable associations in UCS and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for C6orf120 RNA expression.
This table summarizes C6orf120 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C6orf120. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C6orf120 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in HNSC, LIHC and KIRP. The HNSC box plot shows higher C6orf120 RNA expression in tumor versus normal tissue (log2 FC = +0.537, t-test p < 0.001).
This table shows molecular features associated with C6orf120 in patient tissues and cancer cell lines. In patient samples, C6orf120 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C6orf120 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
